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Ceramide lipids have emerged as important intracellular signalling molecules that mediate diverse cellular effects, of which programmed
cell death, or apoptosis, has attracted significant interest. Although the exact mechanism(s) by which ceramides trigger apoptosis is not fully
understood, there is considerable evidence that they are key mediators of this response. Exogenously applied, cell-permeable ceramides have
been shown to induce apoptosis when incubated with cells in culture. We examined here the cytotoxicity of ceramides with varying acyl
chain lengths in order to determine whether acyl chain length affects pro-apoptotic activity within the concentration range of 0–100 AM. We
found that for C6-, C8-, C10-, C14- and C16-ceramide, the chain length was inversely proportional to cytotoxic activity, with C6-ceramide
being most active (IC50 values in the 3–14 AM range) and C16-ceramide being least active (IC50 values in excess of 100 AM) in the
MDA435/LCC6 human breast cancer and J774 mouse macrophage cell lines investigated. Using these two ceramide forms we were able to
correlate the observed cytotoxicity with cellular uptake, and we observed that a lack of intracellular delivery may be responsible for the weak
activity of C16-ceramide. We therefore investigated the possibility of incorporating ceramide lipids into liposome bilayers to enhance this
delivery. We demonstrate that stable, ceramide-containing liposomes can be formulated, and that they are cytotoxic when taken up by cells in
vitro. These results provide an increased understanding of the differences in cytotoxic activity of exogenous short- and long-chain ceramide
lipids, and their incorporation into biologically active liposomal formulations opens new avenues for apoptosis induction.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Sphingolipid; Ceramide; Apoptosis; Liposome; Bioactive lipid0005-2736/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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Abbreviations: C2-ceramide, N-acetoyl-D-erythrosphingosine; C6-ce-
ramide, N-hexanoyl-D-erythrosphingosine; C8-ceramide, N-octanoyl-D-
erythrosphingosine; C10-ceramide, N-decanoyl-D-erythrosphingosine;
C14-ceramide, N-myristoyl-D-erythrosphingosine; C16-ceramide, N-palmi-
toyl-D-erythrosphingosine; IC50, 50% inhibitory concentration; nSMase,
neutral sphingomyelinase; aSMase, acid sphingomyelinase; GlcCer, gluco-
sylceramide; MDR, multidrug resistance; GCS, glucosylceramide synthase;
MTT, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide];
CHE, cholesterylhexadecylether; DMEM, Dulbecco’s Modified Eagle’s
Medium; Hanks, Hanks Balanced Salt Solution; EDTA, ethylenediaminete-
traacetic acid; ATCC, American Type Culture Collection; Abs, absorbance;
DPPC, dipalmitoyl phosphatidylcholine; DSPC, disteroyl phosphatidylcho-
line; CHEMS, cholesteryl hemisuccinate; Chol, cholesterol; BCA, bicin-
choninic acid; BSA, bovine serum albumin; Cer, ceramide
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Sphingolipids are a complex and diverse group of
lipids that has gained much attention as intracellular
signalling molecules involved in cell differentiation, cell
cycle arrest, senescence and apoptosis [1–3]. The
sphingolipid ceramide has been identified as an impor-
tant second messenger that mediates these effects, and
its specific involvement in apoptosis has attracted sig-
nificant interest. Intracellular ceramide may be generated
by hydrolysis of the membrane lipid sphingomyelin via
plasma membrane and cytosolic forms of neutral sphin-
gomyelinase enzymes (nSMases), via endosomal/lysoso-
mal acid sphingomyelinases (aSMases), or via de novo
synthesis from serine and palmitoyl CoA by ceramide
synthase. The exact mechanism by which ceramide
elicits apoptosis has not been fully elucidated, and the
pathways appear to be both stimulus- and cell type-
specific. However, ceramide lipids are known to partic-ed.
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threonine kinases and by stimulating protein phosphatases.
Emerging evidence also suggests that sphingomyelin-
enriched lipid domains or ‘‘rafts’’ may serve as substrate
pools for SMase-induced formation of ceramide micro-
domains that act as platforms from which these signal
transduction cascades originate [4]. Ceramides have also
been shown to exert direct effects on mitochondria [5,6],
and one mechanism that has been proposed for ceramide-
mediated apoptosis is via channel or pore formation in
mitochondrial membranes [7].
The emerging role for ceramide in apoptosis makes
it an attractive intracellular target from a therapeutic
perspective. Exogenous, cell-permeable ceramides have
been shown to result in tumor cell apoptosis in a
number of cell lines. Many cancer chemotherapy
modalities, including doxorubicin, daunorubicin, etopo-
side and radiation, act in part by inducing ceramide
generation, and synergistic effects between exogenous
ceramide and anticancer treatments have been reported
[8]. These observations suggest that stimuli which result
in increased intracellular ceramide levels have pro-
apoptotic effects. The involvement of ceramide in
apoptosis was further demonstrated by the finding that
alterations in ceramide metabolism, whereby pro-apop-
totic ceramide is converted to its non-cytotoxic gluco-
sylceramide (GlcCer) metabolite, contribute to the
emergence of multidrug resistance (MDR) [9]. Several
tumor cell lines and clinical samples have been shown
to overexpress the glucosylceramide synthase (GCS)
enzyme which converts ceramide to GlcCer [10]. This
has been correlated with resistance to cytotoxic agents
in vitro and poor response to chemotherapy in cancer
patients. Several studies have since demonstrated that
inhibitors of ceramide metabolism can be used to
chemosensitize resistant cells in vitro [11–15].
The above observations indicate that therapeutic
approaches aimed at increasing intracellular ceramide
levels should lead to an enhanced apoptotic response.
In this paper we used the MTT cytotoxicity assay to
investigate the effect of adding exogenous ceramides
of varying acyl chain lengths to tumor cells in vitro.
We demonstrate that cytotoxicity is dependent on
chain length, and these results were correlated with
cellular uptake of radiolabeled ceramide lipids. We
also investigated the feasibility of using liposomal
delivery systems to enhance intracellular ceramide
accumulation and cytotoxicity. Our aim was to
exploit the ability of liposomes to deliver therapeutic
lipids in order to achieve intracellular delivery of
ceramide lipids. The results of these studies provide
an increased understanding of the basis for the
differences in cytotoxic activity of exogenous short-
and long-chain ceramide lipids, and open opportunities
for therapeutic strategies based on controlled ceramide
delivery.2. Materials and methods
2.1. Materials
All phospholipids and ceramides were obtained from
Avanti Polar Lipids (Alabaster, AL). Cholesterol, choles-
teryl hemisuccinate and MTT reagent were obtained from
Sigma-Aldrich Canada (Oakville, ON, Canada). [3H]Cho-
lesterylhexadecyl ether (CHE) was purchased from Perkin-
Elmer (Boston, MA). [14C]C6- and [
14C]C16-ceramide
were purchased from American Radiolabeled Chemicals
(St. Louis, MO). Dulbecco’s Modified Eagle’s Medium
(DMEM) and Hanks Balanced Salt Solution (without pH
indicator; Hanks) were obtained from Stem Cell Technol-
ogies (Vancouver, BC, Canada). Fetal bovine serum was
purchased from Hyclone (Logan, UT). L-Glutamine and
trypsin-EDTA were obtained from Gibco BRL (Burlington,
ON, Canada). The Micro BCA Protein Assay kit was
purchased from Pierce (Rockford, IL). Tissue culture
flasks, incubation plates and cell scrapers were obtained
from Falcon (Becton Dickinson, Franklin Lakes, NJ).
2.2. Cell lines and culture
Human estrogen receptor negative MDA435/LCC6 wild-
type and MDR-1 gene-transfected MDA435/LCC6MDR1
multidrug resistant breast cancer cell lines were a generous
gift from Dr. Robert Clark, Georgetown University, Wash-
ington, DC. J774 murine macrophage cells were obtained
from ATCC (Rockville, MD). All cells were grown as
adherent monolayer cultures in 25-cm2 Falcon flasks in
DMEM supplemented with 10% fetal bovine serum and
1% L-glutamine. Cells were maintained at 37 jC in humidi-
fied air with 5% CO2. Cells were subcultured weekly using
0.25% trypsin with 1 mM EDTA (MDA435/LCC6) or
gentle cell scraping (J774).
2.3. Preparation of liposomes
Lipids were weighed into individual test tubes and
dissolved in 1 ml of chloroform (DPPC, DSPC, CHEMS,
Chol), ethanol (C2-, C6-, C8-, C10-, C14-ceramide) or chloro-
form/methanol (2:1, v/v; C16-ceramide). C16-ceramide
required brief heating at 65 jC to achieve complete dis-
solution. Appropriate volumes of each lipid were transferred
to a single tube in order to achieve the desired ratio of each
lipid component. All ratios indicated in this research are on
a mole/mole basis. [3H]CHE was incorporated at 1 ACi/mg
lipid as a nonexchangeable, non-metabolizable lipid marker
[16] to facilitate liposome quantitation. For the preparation
of ceramide-containing liposomes, [14C]C6-ceramide or
[14C]C16-ceramide was incorporated into the formulation
at 0.5 ACi/mg ceramide. The mixtures were evaporated with
vortexing and heating under a stream of nitrogen gas and
subjected to vacuum drying for a minimum of 4 h to
produce a homogenous lipid film. The lipid film was
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mM HEPES/150 mM NaCl; pH 7.4) with vortexing.
Homogeneously sized liposomes were then produced fol-
lowing a 10-cycle extrusion through three stacked 100-nm
polycarbonate filters (Nucleopore, Canada) at 65 jC for
non-ceramide formulations and 95 jC for ceramide formu-
lations, using an extrusion apparatus (Lipex Biomembranes,
Vancouver, BC, Canada). The resulting mean liposome
diameter obtained following extrusion was within a range
of 91–132 nm, depending on lipid composition, as deter-
mined by quazi-elastic light scattering using the Nicomp
270 submicron particle sizer model 370/270 [17,18]. Lip-
osome and ceramide concentrations were determined by
liquid scintillation counting.
2.4. Cytotoxicity assays
Cell suspensions were diluted 1:1 with trypan blue,
counted with a hemocytometer and seeded into 96-well
microtiter plates at 1.5 106 cells/well in 0.2-ml complete
medium. The perimeter wells were not used and contained
0.2-ml sterile water. The cells were allowed to adhere for 24 h
at 37 jC, after which the medium was aspirated and replaced
with 0.1-ml fresh medium. Free ceramide, control liposome
or ceramide-liposome stocks were diluted into complete
medium and added to cells in 0.1 ml to achieve the desired
final concentration. The C16-ceramide stock was kept warm
and diluted into warm medium prior to addition to the cells,
and remained in solution at all times. After 72 h the cell
viability was assessed using a conventional 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
dye reduction assay. Fifty microliters of 5 mg/ml MTT
reagent in phosphate buffered saline (PBS) was added to
each well. Viable cells with active mitochondria reduce the
MTT to an insoluble purple formazan precipitate that is
solubilized by the subsequent addition of 150-Al dimethyl
sulfoxide. The formazan dye was measured spectrophoto-
metrically using a Dynex plate reader (570 nm). All assays
were performed in triplicate. The cytotoxic effect of each
treatment was expressed as percent cell viability relative to
untreated control cells (% control) and is defined as: [(Abs570
treated cells)/(Abs570 control cells)] 100.
2.5. Lipid uptake studies
Cell suspensions were diluted 1:1 with trypan blue,
counted with a hemocytometer and seeded into six-well
Falcon plates at 2.5 105 cells/well in 2-ml complete
medium. The cells were allowed to adhere for 24 h at
37 jC, after which the medium was aspirated and replaced
with 1-ml complete medium. Free ceramide, control lip-
osome or ceramide-liposome stocks were diluted in 1-ml
complete medium and added to each well to give the
desired final concentration. Cells were incubated with the
treatments for 1, 4 and 24 h at 37 jC. The incubation
medium was then aspirated and cells were washed twicewith 2-ml Hanks. Cells were gently scraped into 0.5-ml
Hanks and collected into glass scintillation vials using
glass pipettes. Each well was rinsed with an additional
0.5-ml Hanks to remove residual cells. An aliquot of cells
was removed for protein quantification and the remainder
was counted for radioactivity by scintillation counting.
2.6. Spectrophotometric protein quantification
The protein content of each cell aliquot was determined
using the Pierce Micro BCA Protein Assay according to the
method included with the assay kit. Briefly, a standard curve
was prepared using the supplied purified bovine serum
albumin (BSA) diluted in distilled water to a final volume
of 0.5 ml. Samples were prepared using 5 Al cell suspension+
495 Al dH2O. Micro BCA reagents A, B and C were added in
the specified ratios. All samples and standards were prepared
in glass test tubes. which were heated in a 65 jC water bath
for 1 h and cooled to room temperature. The absorbance at
562 nm of each sample was read against a dH2O reference.
The protein concentration for each cell sample was deter-
mined using a standard curve prepared from the known BSA
samples.3. Results
3.1. Chain length dependence of free ceramide cytotoxicity
in the MDA435/LCC6 human breast cancer cell line
The cytotoxic activity of exogenously applied ceramides
with increasing acyl chain length was evaluated by incubat-
ing the MDA435/LCC6 and MDA435/LCC6MDR1 cells with
C2- C6- C8- C10- C14- and C16-ceramide over a range of 0–
100 AM final ceramide concentration. The 72 h MTT cyto-
toxicity results shown in Fig. 1 demonstrate that cytotoxic
activity is dependent on ceramide acyl chain-length. With the
exception of C2-ceramide, as acyl chain length increased the
cytotoxic activity decreased. This trend may be explained by
the cell-permeability characteristics of the various acyl chain
lengths. In order to be active, the exogenous ceramide must
transfer from the tissue culture medium in which it is
dissolved, cross the plasma membrane of the cell and then
exchange into cellular membranes from which it can interact
with it intracellular target(s). The C2-ceramide, being very
hydrophillic, likely remains dispersed in the tissue culture
media, which is consistent with its IC50 values of 74 and 79
AM for the wild-type and MDR cell lines, respectively (Table
1). The C6- and C8-ceramides are the most cytotoxic, with
IC50 values in the 3–14 AM range. As the chain length
increases to C10-, C14- and C16-ceramide the hydrophobic
nature also increases, and IC50 values of approximately 45
AM are observed for C10-ceramide and in excess of 100 AM
are observed for C14- and C16-ceramides. From these results
we identified C6-ceramide as the most potent exogenous
ceramide form.
Fig. 2. Cellular uptake of C6- and C16-ceramide by wild-type (A) and
MDR-1 gene transfected (B) MDA435/LCC6 cells. Cells were incubated
with 1.0 AM C6-ceramide or 50 AM C16-ceramide for the times indicated.
[14C]C6- or [
14C]C16-ceramide was added at 0.1 ACi/nmol ceramide for
quantitation by scintillation counting. Cellular protein content was
measured spectrophotometrically (Abs 562 nm) using the micro BCA
protein assay kit. Data are averaged means from two triplicate experiments;
bars, S.D.
Fig. 1. Cytotoxicity of various acyl chain length free ceramide lipids on
wild-type (A) and MDR-1 gene transfected (B) MDA435/LCC6 human
breast cancer cells. Cells were incubated with the indicated ceramide
concentrations for 72 h and cell viability was measured using the MTT
assay. Data are averaged means from three triplicate experiments. Each
value represents the mean from at least three independent experiments;
bars, S.D.
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uptake levels
In order to examine whether acyl chain length deter-
mines ceramide cytotoxicity because of differences in
cell-permeability, we conducted cellular uptake studies
using radioactive C6- and C16-ceramides. Fig. 2 showsTable 1
IC50 values for various chain length free ceramide lipids incubated with wild-typ
Cell line IC50
aF S.E. (AM)
C2-Cer C6-Cer C
MDA435/LCC6 73.60F 7.92 2.71F 0.69
MDA435/LCC6MDR1 79.20F 6.04 5.67F 0.70 1
a Cells were incubated with increasing concentrations of free ceramide lipid ov
value was taken as the ceramide concentration that inhibits cell growth by 50% re
three independent experiments conducted in triplicate. The S.E.M. represents thethat for both the wild-type and resistant cell lines,
[14C]C6-ceramide levels steadily increased to 7 pmol
ceramide/Ag protein over the 24-h incubation period
while [14C]C16-ceramide levels remained under 2 pmol
ceramide/Ag protein. These relative differences are con-
sistent with the lack of C16-ceramide-induced cytotoxic-
ity.e and MDR-1 gene-transfected MDA435/LCC6 human breast cancer cells
8-Cer C10-Cer C14-Cer C16-Cer
7.00F 3.25 44.10F 2.69 >100 >100
3.95F 2.19 46.00F 1.39 >100 >100
er 72 hours and cell viability was measured using the MTT assay. The IC50
lative to untreated control cells. Data are average IC50 values obtained from
standard error associated with the resulting three mean values.
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MDA435/LCC6 cells
Since C6-ceramide was identified as the most potent
exogenous ceramide lipid, we attempted to formulate it into
liposomes to further enhance its intracellular delivery. Lip-
osomes containing up to 15 mol% C6-ceramide were suc-
cessfully formulated, with an overall composition of C6-
ceramide/DSPC/Chol (15:40:45) and a mean diameter of
98–117 nm. Fig. 3 demonstrates that C6-ceramide lipo-
somes are cytotoxic to cells in vitro, with IC50 values of
15.9 and 18.2 AM for the wild-type and MDR-1 gene-
transfected MDA435/LCC6 cells, respectively. The cytotox-
icity was ceramide-specific, as control liposomes composed
of DSPC/Chol (55:45) that do not contain ceramide in the
bilayer displayed no activity. These results were then
correlated with cellular uptake. For these studies lipid
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wild-type (A) and MDR-1 gene-transfected (B) MDA435/LCC6 cells.
Uptake of [3H]CHE bulk liposomal lipid and [14C]C6-ceramide is expressed
as percent of the total radioactivity added, normalized to 105 cells. Data are
averaged means from two triplicate experiments; bars, S.D.
Fig. 3. Cytotoxicity of control (DSPC/Chol, 55:45) and C6-ceramide (C6-
ceramide/DSPC/Chol, 15:40:45) liposomes on wild-type (A) and MDR-1
gene-transfected (B) MDA435/LCC6 human breast cancer cells. Cells were
incubated with the indicated concentrations of liposomes for 72 h and cell
viability was measured using the MTT assay. The indicated liposome
concentration represents total lipid for control liposomes and was corrected
for ceramide content for ceramide-containing liposomes. Data are averaged
means from three triplicate experiments; bars, S.D.uptake was expressed as a percent of the total radioactivity
added in order to allow for direct comparisons to be made
between the ceramide lipid and bulk liposomal lipid. The
results in Fig. 4 indicate that the [14C]C6-ceramide compo-
nent of the liposomes was taken up by the tumor cells,
approaching 80% internalization after 24 h, whereas less
than 10% of the [3H]CHE liposome label was cell-associ-
ated after 24 h. These results suggest that the C6-ceramide is
being delivered not via the liposomes, but rather by
exchange from the liposome bilayer into cellular membranes
in a manner similar to that following addition of non-
liposomal C6-ceramide.
3.4. Formulation and activity of C16-ceramide liposomes in
MDA435/LCC6 cells
Since formulation of C6-ceramide into liposomes did not
appear to afford any delivery benefit, we decided to inves-
tigate whether the more physiologically relevant long-chain
C16-ceramide, which was not cytotoxic in its free form,
could be made active by delivering it via liposomes. We
Fig. 5. Cytotoxicity of control (DPPC/CHEMS, 50:50) and C16-ceramide
(C16-ceramide/CHEMS, 50:50) liposomes on wild-type (A) and MDR-1
gene-transfected (B) MDA435/LCC6 human breast cancer cells. Cells were
incubated with the indicated concentrations of liposomes for 72 h and cell
viability was measured using the MTT assay. The indicated liposome
concentration represents total lipid for control liposomes and was corrected
for ceramide content for ceramide-containing liposomes. Data are averaged
means from three triplicate experiments; bars, S.D.
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successfully formulated into liposomes with an overall
composition of C16-ceramide/DSPC/Chol (15:40:45) and a
mean diameter in the range of 91–124 nm. However, when
incubated with cells in the MTT assay, we found that the
cytotoxicity of C16-ceramide-containing liposomes was
comparable to control DSPC/Chol (55:45) liposomes. This
was correlated with cellular uptake studies indicating that
less than 10% of the [3H]CHE and [14C]C16-ceramide labels
were internalized after 24 h (data not shown).
The inability of liposomes to enhance the cytotoxicity of
C16-ceramide appeared to be attributed to a lack of internal-
ization of the liposomes by the MDA435/LCC6 cells. In
order to enhance internalization of ceramide-containing lip-
osomes, we formulated C16-ceramide into negatively
charged liposomes in an attempt to increase the interaction
of the liposomes with the target cells. To accomplish this
goal, we utilized cholesteryl hemisuccinate (CHEMS), an
acidic cholesterol ester that can be incorporated into lip-
osomes to impart pH sensitivity and fusogenic properties
[19,20]. Our objectives in incorporating this lipid into our
ceramide-containing liposomes were first, to use its negative
charge to increase the interaction between the liposomes and
cells, and second, to exploit the pH sensitivity of the lipid to
trigger liposome destabilization upon intracellular delivery
via endocytosis. We observed that C16-ceramide could be
incorporated into CHEMS containing liposomes at up to 50
mol%, for a final liposome composition of C16-ceramide/
CHEMS (50:50). These liposomes were stable and dis-
played a mean diameter range of 97–132 nm. Fig. 5 shows
that C16-ceramide/CHEMS liposomes provided a modest
increase in the cytototoxicity of free C16-ceramide; however,
the IC50 remained greater than 100 AM. This improvement
in activity was not attributable to the negative charge of the
CHEMS liposomes, as control liposomes composed of
DPPC/CHEMS (50:50) showed no activity. The non-ceram-
ide lipid of the control liposomes in this case was changed
from DSPC to DPPC to more closely match the 16-carbon
acyl chain length of the ceramide.
3.5. Cytotoxicity of ceramide lipids in the J774 murine
macrophage cell line
The modest improvement in activity afforded by the
CHEMS liposomes gave us a preliminary indication that
liposomal delivery of C16-ceramide may be effective if
efficient intracellular delivery could be achieved. In order
to demonstrate this from a proof-of-principle perspective,
we utilized the J774 murine macrophage cell line, which
provides enhanced liposome endocytosis and therefore
intracellular delivery of the liposomes to their intended
target (endosomes/lysosomes) where pro-apoptotic ceram-
ide is known to be endogenously generated by aSMases
[21–23]. Identification of the endosomal acidic aspartate
protease cathepsin D as a ceramide binding target has been
implicated as a mediator of this response [24,25].Before investigating the effect of ceramide-containing
liposomes on J774 cells, we first examined whether free
ceramide lipids had the same effect on J774 cells as we
observed in the MDA435/LCC6 cells. As shown in Fig. 6,
the same chain length dependence of free ceramide cytotox-
icity was observed, with the short-chain C6- and C8-ceram-
ides being the most active (IC50 values of 14.4 AM for both)
and C16-ceramide showing no activity.
The MTT cytotoxicity results shown in Fig. 7 indicate
that liposomes composed of C16-ceramide/CHEMS (50:50)
dramatically improved the cytotoxicity of C16-ceramide in
the J774 macrophage cell line. Specifically, while the IC50
value of C16-ceramide, when exogenously applied to these
cells in non-liposomal form, was well in excess of 100 AM,
its formulation and delivery via CHEMS liposomes
decreased the IC50 to 36.1 AM, bringing it into the range
of cytotoxicity observed with free C6-ceramide (14.4 AM).
Fig. 8. Cellular uptake of C16-ceramide/CHEMS (50:50) liposomes by J774
murine macrophage cells. Uptake of [3H]CHE bulk liposomal lipid and
[14C]C16-ceramide are expressed as percent of the total radioactivity added,
normalized to 105 cells. Data are averaged means from two triplicate
experiments; bars, S.D.
Fig. 6. Cytotoxicity of various acyl chain length free ceramide lipids on
J774 murine macrophage cells. Cells were incubated with the indicated
ceramide concentrations for 72 h and cell viability was measured using the
MTT assay. Data are averaged means from three triplicate experiments.
Each value represents the mean from at least three independent experi-
ments; bars, S.D.
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attributed to the presence of CHEMS lipid alone, as control
DPPC/CHEMS (50:50) liposomes were non-cytotoxic. Cel-
lular uptake studies showed that both the liposome and the
ceramide components were internalized, as evidenced by
uptake of the [3H]CHE and [14C]C16-ceramide labels, which
both approached 50% after 24 h (Fig. 8). This indicates that
the C16-ceramide lipid is being delivered via liposomes
(rather than by passive lipid exchange), and demonstratesFig. 7. Cytotoxicity of control (DPPC/CHEMS, 50:50) and C16-ceramide
(C16-ceramide/CHEMS, 50:50) liposomes on J774 murine macrophage
cells. Cells were incubated with the indicated concentrations of liposomes
for 72 h and cell viability was measured using the MTT assay. The indicated
liposome concentration represents total lipid for control liposomes and was
corrected for ceramide content for ceramide-containing liposomes. Data are
averaged means from three triplicate experiments; bars, S.D.that endosomal delivery of these liposomes can enhance
ceramide-induced apoptosis.4. Discussion
The field of sphingolipid biology is rapidly developing,
with great emphasis on ceramide lipids as mediators of
diverse biological effects. Of these effects, research in the
area of ceramide lipids and apoptosis has received consid-
erable interest, both from a mechanistic [6,7,26–28] and a
therapeutic [29,30] perspective. Modulation of intracellular
ceramide levels is not a novel concept. Ceramide has been
shown to increase dramatically following exposure to a
number of cytotoxic insults, including anticancer drugs
and radiation. Addition of exogenous, cell-permeable
ceramides has been shown to induce apoptosis in many cell
lines. In this approach research has largely focused on the
C6-ceramide form, which has received some criticism in the
literature because it is perhaps not a physiologically relevant
ceramide form. Nevertheless, it does induce apoptosis and
therefore may be useful from a therapeutic, if not a mech-
anistic, perspective. Other approaches aimed at promoting
endogenous ceramide formation and/or inhibiting endoge-
nous ceramide metabolism have also shown promise in both
in vitro and in vivo models [11]; reviewed in Refs. [29,31].
In the present investigation, our first objective was to
examine the effect of different acyl chain length synthetic
ceramides on in vitro cytotoxicity using the MDA435/LCC6
wild-type and MDR-1 gene-transfected MDA435/LCC6
cell lines. We observed an inverse relationship between acyl
chain length and cytotoxicity for the C6 to C16-ceramide
forms, with C6- showing the most activity (IC50 values in
the 3–14 AM) whereas C16-ceramide showed no cytotoxic
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able to correlate these differences with uptake of radioactive
[14C]C6- and [
14C]C16-ceramide and demonstrated that
short-chain ceramide uptake was more than threefold greater
than that of long-chain ceramide (7 versus 2 pmol cer/Ag
protein). It is important to highlight that no differences were
observed between the wild-type and MDR-1 gene-trans-
fected cells with respect to ceramide-induced cytotoxicity or
uptake. This is significant because it suggests that ceramide-
based therapies may be equally effective in the treatment of
sensitive and MDR tumors that overexpress Pgp.
As noted by Hannun and Luberto in a recent review, it is
important to consider that the relevant concentration of cell-
associated ceramide represents the total membrane ceramide
concentration. Since this is highly dependent on factors such
as cell density, it is important that experimental conditions
be uniform and consistent in order for valid comparisons to
be made between different treatments and/or experiments
[30].
The observed relationship between acyl chain length,
cytotoxicity and uptake led us to speculate about the possi-
bility of incorporating ceramide lipids into liposome bilayers
to enhance intracellular delivery. Liposomes containing 15
mol% C6-ceramide were successfully formulated into DSPC/
Chol liposomes and were demonstrated to be cytotoxic to
MDA435/LCC6 cells in vitro. However, uptake studies
demonstrated that the activity was attributed to ceramide
lipid exchange from the liposome bilayer to the cell mem-
branes, rather than by delivery via liposomes (80% cell-
associated C6-ceramide versus less than 10% cell-associated
liposomal lipid). This supports our contention that C6-ceram-
ide is cytotoxic due to its ability to readily exchange between
intracellular membrane pools. The amphipathic nature of C6-
ceramide affords it sufficient solubility to disperse in aqueous
cell culture media, but also provides the hydrophobic char-
acter required for the permeation of cell membranes to reach
intracellular target(s). This exchangeability is supported by
observations of C6-ceramide transfer between lipid vesicles
[32]. Thus, the liposomes neither enhanced ceramide delivery
nor improved ceramide cytotoxicity beyond that observed
following delivery of short-chain ceramide in its free form,
and therefore the liposomes provided no therapeutic advant-
age to the already active short-chain ceramide. This prompted
us to turn our attention to natural ceramide in an attempt to
design liposomes that incorporate C16-ceramide in the
bilayer. This was done on the basis that C16-ceramide is more
likely to remain associated with the liposome during delivery
and does not passively exchange from the liposome bilayer in
which it is stably incorporated. This is supported by the work
of Simon et al., who observed that exchange of [14C]C16-
ceramide between phospholipid vesicles occurred on the
order of days (t1/2 of 49–105 h) [33], as well as similar
observations made by our lab [32]. Furthermore, C16-ceram-
ide is the more physiologically relevant form, and both short-
and long-term increases in C16-ceramide accumulation have
been observed during apoptosis [34]. We found that up to 15mol% C16-ceramide could be successfully formulated into
DPPC/Chol liposomes. However, these liposomes did not
appear to be active in vitro, with IC50 values well in excess of
100 AM in the MDA435/LCC6 cell line. Uptake studies
revealed that this was attributed to lack of internalization of
the liposomes themselves. This was perhaps not surprising, as
cells do not readily endocytose liposomes in the absence of
targeting ligands or surface charge.
In order to address this issue, we changed the liposome
formulation to incorporate the pH-sensitive CHEMS lipid,
which would increase liposome interaction with the target
cells due to the negative surface charge and also become
fusogenic once exposed to the acidic pH of the endosomes
and lysosomes. We also changed the target cells to the
murine macrophage J774 cell line, which is known to
readily endocytose liposomes. This helped to ensure that
the ceramide would be specifically delivered to the endo-
somal target site. We observed that up to 50 mol% C16-
ceramide could be successfully formulated into CHEMS-
containing liposomes, and we demonstrated that these
liposomes were indeed cytotoxic with an IC50 value of
36.1 AM, which approached that of free C6-ceramide (14.4
AM). We further demonstrated that both the ceramide and
lipid components of the C16-ceramide formulation are
internalized, which indicates that the liposome is acting
as a biologically active ceramide delivery vehicle.
These results clearly demonstrate the importance intra-
cellular delivery for the application of exogenous ceramide
lipids as therapeutically active inducers of apoptosis.
Although short-chain, cell-permeable ceramides show activ-
ity on their own, their rapid exchange between lipid mem-
branes limits their ability to be used for controlled ceramide
delivery purposes. Furthermore, one must be cautious when
extrapolating observations obtained using short-chain, exog-
enous ceramides to the physiological setting, as their bio-
physical properties differ from those of natural ceramides.
The results presented here address both of these issues.
First, by using a liposome-based system the ceramide lipids
can be delivered in a much more controlled and specific
manner. Second, this work avoids potential complications
associated with the use of synthetic ceramide analogues by
delivering physiologically relevant endogenous C16-ceram-
ide to specific organelles (endosomes/lysosomes) associated
with natural ceramide production in response to apoptotic
stimuli. Taken together, these results provide the basis for
the development of therapeutically active ceramide-based
liposomes, which have the potential to be pursued as novel
inducers of apoptosis.Acknowledgements
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